Counteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common form of dementia, and neuroinflammation is an important hallmark of the pathogenesis. Tumor necrosis factor (TNF) might be detrimental in AD, though the results coming from clinical trials on anti-TNF inhibitors are inconclusive. TNFR1, one of the TNF signaling receptors, contributes to the pathogenesis of AD by mediating neuronal cell death. The blood-cerebrospinal fluid (CSF) barrier consists of a monolayer of choroid plexus epithelial (CPE) cells, and AD is associated with changes in CPE cell morphology. Here, we report that TNF is the main inflammatory upstream mediator in choroid plexus tissue in AD patients. This was confirmed in two murine AD models: transgenic APP/PS1 mice and intracerebroventricular (icv) AβO injection. TNFR1 contributes to the morphological damage of CPE cells in AD, and TNFR1 abrogation reduces brain inflammation and prevents blood-CSF barrier impairment. In APP/PS1 transgenic mice, TNFR1 deficiency ameliorated amyloidosis. Ultimately, genetic and pharmacological blockage of TNFR1 rescued from the induced cognitive impairments. Our data indicate that TNFR1 is a promising therapeutic target for AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
The novel object recognition memory: neurobiology, test procedure, and its modifications
Antunes, M., & Biala, G. (2012) · Cognitive Processing · doi:10.1007/s10339-011-0430-z · Cited by 2,390 · cited 2×
“Cognitive behavior was assessed by the basic protocol for the NOR test described by Antunes and Biala (2012).”
Synaptic scaling mediated by glial TNF-α
Stellwagen, D., & Malenka, R. C. (2006) · Nature · doi:10.1038/nature04671 · Cited by 1,715 · cited 1×
“It regulates synaptic communication between neurons and thereby regulates brain function in health and in disease (Stellwagen & Malenka, 2006; McCoy & Tansey, 2008).”
Serial Block-Face Scanning Electron Microscopy to Reconstruct Three-Dimensional Tissue Nanostructure
Denk, W., & Horstmann, H. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020329 · Cited by 1,644 · cited 1×
“Serial block-face SEM (SBF-SEM) is an application used to generate electron microscopy image stacks that are reconstructed to generate 3D images (Denk & Horstmann, 2004).”
Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.49 · Cited by 1,288
Systemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 1×
“Neuroinflammation is an important hallmark of brain pathology (Akiyama et al , 2000), and both acute and chronic inflammation are associated with cognitive decline (Holmes et al , 2009).”
Bezzi, P., Domercq, M., Brambilla, L., Galli, R., Schols, D., De Clercq, E., Vescovi, A., Bagetta, G., Kollias, G., Meldolesi, J., et al. (2001) · Nature Neuroscience · doi:10.1038/89490 · Cited by 1,102
Yang, Y., Estrada, E. Y., Thompson, J. F., Liu, W., & Rosenberg, G. A. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600375 · Cited by 1,060
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · cited 1×
“Numerous studies indicate that neurovascular dysfunction and perturbation of the central nervous system (CNS) barriers contribute to the onset and progression of AD (Zenaro et al , 2017).”
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Takeuchi, H., Jin, S., Wang, J., Zhang, G., Kawanokuchi, J., Kuno, R., Sonobe, Y., Mizuno, T., & Suzumura, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600504200 · Cited by 749 · cited 1×
“Indeed, TNF has been shown to induce the release of glutamate from microglia and astrocytes via TNFR1 signaling and might directly induce glutamate excitotoxicity via TNFR1 through activation of AMPA receptors (Bezzi et al , 2001; Kuno et al , 2005; Takeuchi et al , 2006).”
Tumor necrosis factor alpha: A link between neuroinflammation and excitotoxicity
Olmos, G., & Lladó, J. (2014) · Mediators of Inflammation · doi:10.1155/2014/861231 · Cited by 730 · cited 1×
“Conversely, TNFR2 activation protects against glutamate-induced excitotoxicity (Marchetti et al , 2004; Olmos & Llado, 2014).”
Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease
Agostinho, P., A. Cunha, R., & Oliveira, C. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793176572 · Cited by 685
Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
Viola, K. L., & Klein, W. L. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1386-3 · Cited by 628 · cited 1×
“…form between monomeric A b and A b fibrils — has gained increasing attention as the major toxic species driving the neuroinflammation associated with Alzheimer’s disease rather than the A b plaques themselves (Nitta et al , 1997; Brkic et al , 2015b; Ferreira et al , 2015; Viola & Klein, 2015).”
Intrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · cited 1×
“…A b plaques and the elevated TNF levels in the plasma and cerebrospinal fluid (CSF) of AD patients, both of which have been associated with clinical deterioration (Fillit et al , 1991; Dickson, 1997; Paganelli et al , 2002; Tarkowski et al , 2003a,b; Yasutake et al , 2006; Swardfager et al , 2010).”
Baruch, K., Rosenzweig, N., Kertser, A., Deczkowska, A., Sharif, A. M., Spinrad, A., Tsitsou-Kampeli, A., Sarel, A., Cahalon, L., & Schwartz, M. (2015) · Nature Communications · doi:10.1038/ncomms8967 · Cited by 491 · cited 1×
“However, in AD this gate-way system is altered, resulting in suboptimal recruitment of inflammation-resolving immune cells to the brain (Baruch et al , 2015).”
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390 · cited 5×
“More-over, TNFR1 inhibition by a Nanobody recapitulated these findings Amyloidprecursor protein(APP) iscleavedintopathogenicamyloid-beta1 – 42(A b 1 – 42 )speciesbyBACE1,theexpressionofwhichcan beactivatedbyTNFR1-induced NF-j B in neurons of the hippocampus.”
InfluentialFerreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373 · cited 2×
“…form between monomeric A b and A b fibrils — has gained increasing attention as the major toxic species driving the neuroinflammation associated with Alzheimer’s disease rather than the A b plaques themselves (Nitta et al , 1997; Brkic et al , 2015b; Ferreira et al , 2015; Viola & Klein, 2015).”
Yamamoto, M., Kiyota, T., Horiba, M., Buescher, J. L., Walsh, S. M., Gendelman, H. E., & Ikezu, T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060378 · Cited by 367
Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia
Sondag, C. M., Dhawan, G., & Combs, C. K. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-1 · Cited by 295 · cited 1×
“Microglia activation is a prominent hallmark of AD pathology, and it is well documented that both A b O and A b fibrils activate microglia (Sondag et al , 2009).”
Parajuli, B., Sonobe, Y., Horiuchi, H., Takeuchi, H., Mizuno, T., & Suzumura, A. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.503 · Cited by 232 · cited 1×
“Microglia activation precedes cognitive decline in several AD mouse models (Parajuli et al , 2013), and soluble A b O is involved in the induction of cognitive impairment (Ferreira et al , 2015).”
Autocrine activation of microglia by tumor necrosis factor-α
Kuno, R., Wang, J., Kawanokuchi, J., Takeuchi, H., Mizuno, T., & Suzumura, A. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.01.015 · Cited by 232 · cited 2×
“Importantly, A b O induces the release of TNF from microglia, which then stimulates it own release via TNFR1 (Kuno et al , 2005).”
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias
Tarkowski, E., Liljeroth, A.-M., Minthon, L., Tarkowski, A., Wallin, A., & Blennow, K. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00088-1 · Cited by 219 · cited 1×
“…A b plaques and the elevated TNF levels in the plasma and cerebrospinal fluid (CSF) of AD patients, both of which have been associated with clinical deterioration (Fillit et al , 1991; Dickson, 1997; Paganelli et al , 2002; Tarkowski et al , 2003a,b; Yasutake et al , 2006; Swardfager et al , 2010).”
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205 · cited 32×
“Given that disruption of the blood – CSF barrier has been linked to increased activity of matrix metalloproteinases (MMPs) in the choroid plexus (Brkic et al , 2015b), we investigated their expression 6 h after icv injection of A b O. Expression of both Mmp3 and Mmp8 in the choroid plexus was significantly increased a…”
InfluentialSelf-citationMaia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
Treatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis
Chou, R. C., Kane, M., Ghimire, S., Gautam, S., & Gui, J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0374-z · Cited by 194 · cited 1×
“Epidemiological studies indicate that AD is less prevalent in patients on anti-TNF blockers for rheumatoid arthritis (Chou et al , 2016), but clinical trials using anti-TNF blockers in AD patients have been inconclusive (Tobinick et al , 2006; Tobinick & Gross, 2008).”
Alzheimer’s disease and hippocampal adult neurogenesis; exploring shared mechanisms
Hollands, C., Bartolotti, N., & Lazarov, O. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00178 · Cited by 160
Tobinick, E. (2009) · CNS Drugs · doi:10.2165/11310810-000000000-00000 · Cited by 117 · cited 1×
“It has been proposed that the effects of TNF on synapses are associated with the synaptic dysfunction that plays a central role in AD, and particularly in cognitive decline (Tobinick, 2009).”
Montgomery, S. L., Mastrangelo, M. A., Habib, D., Narrow, W. C., Knowlden, S. A., Wright, T. W., & Bowers, W. J. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.001 · Cited by 96
Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease
Jongbloed, W., Bruggink, K. A., Kester, M. I., Visser, P.-J., Scheltens, P., Blankenstein, M. A., Verbeek, M. M., Teunissen, C. E., & Veerhuis, R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142136 · Cited by 68
Montgomery, S. L., Narrow, W. C., Mastrangelo, M. A., Olschowka, J. A., O'Banion, M. K., & Bowers, W. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.02.030 · Cited by 58 · cited 1×
“Also, selective inhibition of neuronal TNFR2 enhanced the A b - and Tau-related pathologic features of AD and diminished the activation of microglia, which is needed for clearance of A b (Montgomery et al , 2013).”
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Bonnardel, J., T’Jonck, W., Gaublomme, D., Browaeys, R., Scott, C. L., Martens, L., Vanneste, B., De Prijck, S., Nedospasov, S. A., Kremer, A., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.017 · Cited by 631
Self-citationApoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
The Impact of Systemic Inflammation on Alzheimer’s Disease Pathology
Xie, J., Van Hoecke, L., & Vandenbroucke, R. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.796867 · Cited by 324
Self-citation
Metadata
- Authors
- Steeland, S., Gorlé, N., Vandendriessche, C., Balusu, S., Brkic, M., Van Cauwenberghe, C., Van Imschoot, G., Van Wonterghem, E., De Rycke, R., Kremer, A., Lippens, S., Stopa, E., Johanson, C. E., Libert, C., & Vandenbroucke, R. E.
- Venue
- EMBO Molecular Medicine
- Published
- 2018-02-22
- Volume
- 10
- Issue
- 4
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2788162126
- Cited by
- 121
- References
- 34
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.